Sequenom (NASDAQ: SQNM) was upgraded by investment analysts at Piper Jaffray from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday.

Sequenom traded up 5.10% on Monday, hitting $4.53. Sequenom has a 1-year low of $2.65 and a 1-year high of $5.83. The stock’s 50-day moving average is currently $4.33. The company’s market cap is $520.0 million.

Sequenom last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.29) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.22) by $0.07. The company had revenue of $33.67 million for the quarter, compared to the consensus estimate of $32.02 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share. The company’s quarterly revenue was up 112.6% on a year-over-year basis. Analysts expect that Sequenom will post $-0.69 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Sequenom in a research note to investors on Friday. They now have a $7.00 price target on the stock. Separately, analysts at Wedbush reiterated a “neutral” rating on shares of Sequenom in a research note to investors on Tuesday, March 5th. They now have a $5.00 price target on the stock. Finally, analysts at Maxim Group reiterated a “buy” rating on shares of Sequenom in a research note to investors on Monday, January 14th. They now have a $7.00 price target on the stock.

Sequenom, Inc. (Sequenom) is a diagnostic testing and genetics analysis company. The Company is focused on providing products, services, diagnostic testing, applications and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock and other areas of research.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.